Pigmented Villonodular Synovitis of the Hip in a Patient with Limited Impairment despite Impressive Radiographic Features

Abstract

We report a case of pigmented villonodular synovitis (PVNS) of the hip joint in a patient with very limited impairment despite impressive radiological features. PVNS activates polyclonal, reactive macrophages with CSF1-receptors. Treatment options are discussed, including new possible therapies with CSF1-receptor inhibitors.

Zusammenfassung

Wir berichten über einen Fall von pigmentierter villonodulärer Synovialitis (PNVS) des Hüftgelenks bei einer Patientin mit sehr geringer Beeinträchtigung trotz großer radiologischer Auffälligkeiten. PVNS aktiviert polyklonale reaktive Makrophagen mit CSF1-Rezeptoren. Wir diskutieren Behandlungsmöglichkeiten, darunter neue Therapiemöglichkeiten mit CSF1-Rezeptor-Inhibitoren.

Key words

pigmented villonodular synovitis - CSF1-receptors-inhibitors

Schlüsselwörter

Pigmentierte villonoduläre Synovialitis - CSF1-Rezeptor-Inhibitoren

• References

• 1 Ravi V, Wang WL, Lewis VO. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis. Curr Opin Oncol 2011; 23: 361-366
• 2 Rubin BP. Tenosynovial giant cell tumor and pigmented villonodular synovitis: a proposal for unification of these clinically distinct but histologically and genetically identical lesions. Skeletal Radiol 2007; 36: 267-268
• 3 Mankin H, Trahan C, Hornicek F. Pigmented villonodular synovitis of joints. J Surg Oncol 103: 386-389
• 4 Gonzalez Della Valle A, Piccaluga F, Potter HG et al. Pigmented villonodular synovitis of the hip: 2- to 23-year followup study. Clin Orthop Relat Res 2001; 187-199
• 5 Zook JE, Wurtz DL, Cummings JE et al. Intra-articular chromic phosphate ((3)(2)P) in the treatment of diffuse pigmented villonodular synovitis. Brachytherapy. 10 190-194
• 6 Shabat S, Kollender Y, Merimsky O et al. The use of surgery and yttrium 90 in the management of extensive and diffuse pigmented villonodular synovitis of large joints. Rheumatology (Oxford) 2002; 41: 1113-1118
• 7 Ward Sr WG, Boles CA, Ball JD et al. Diffuse pigmented villonodular synovitis: preliminary results with intralesional resection and p32 synoviorthesis. Clin Orthop Relat Res 2007; 454: 186-191
• 8 Ottaviani S, Ayral X, Dougados M et al. Pigmented villonodular synovitis: a retrospective single-center study of 122 cases and review of the literature. Semin Arthritis Rheum 40: 539-546
• 9 Chin KR, Barr SJ, Winalski C et al. Treatment of advanced primary and recurrent diffuse pigmented villonodular synovitis of the knee. J Bone Joint Surg Am 2002; 84-A: 2192-2202
• 10 Bickels J, Isaakov J, Kollender Y et al. Unacceptable complications following intra-articular injection of yttrium 90 in the ankle joint for diffuse pigmented villonodular synovitis. J Bone Joint Surg Am 2008; 90: 326-328
• 11 O’Sullivan B, Cummings B, Catton C et al. Outcome following radiation treatment for high-risk pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 1995; 32: 777-786
• 12 Horoschak M, Tran PT, Bachireddy P et al. External beam radiation therapy enhances local control in pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 2009; 75: 183-187
• 13 Blanco CE, Leon HO, Guthrie TB. Combined partial arthroscopic synovectomy and radiation therapy for diffuse pigmented villonodular synovitis of the knee. Arthroscopy 2001; 17: 527-531
• 14 Berger B, Ganswindt U, Bamberg M et al. External beam radiotherapy as postoperative treatment of diffuse pigmented villonodular synovitis. Int J Radiat Oncol Biol Phys 2007; 67: 1130-1134
• 15 Kroot EJ, Kraan MC, Smeets TJ et al. Tumour necrosis factor alpha blockade in treatment resistant pigmented villonodular synovitis. Ann Rheum Dis 2005; 64: 497-499
• 16 Fiocco U, Sfriso P, Oliviero F et al. Intra-articular treatment with the TNF-alpha antagonist, etanercept, in severe diffuse pigmented villonodular synovitis of the knee. Reumatismo 2006; 58: 268-274
• 17 Kobak S. Intraarticular adalimumab in a patient with pigmented villonodular synovitis. Rheumatol Int 31: 251-254
• 18 Snoots WM, Watkins D, Dockery D et al. Pigmented villonodular synovitis responsive to imatinib therapy. Proc (Bayl Univ Med Cent). 24 134-138
• 19 Blay JY, El Sayadi H, Thiesse P et al. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008; 19: 821-822
• 20 Cassier PA, Gelderblom H, Stacchiotti S et al. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis. Cancer
• 21 Ravi V, Wang WL, Araujo DM et al. Imatinib in the treatment of tenosynovial giant-cell tumor and pigmented villonodular synovitis. Journal of Clinical Oncologie 2010; 28 (suppl) 10011
• 22 Chiari C, Pirich C, Brannath W et al. What affects the recurrence and clinical outcome of pigmented villonodular synovitis?. Clin Orthop Relat Res 2006; 450: 172-178
• 23 Vastel L, Lambert P, De Pinieux G et al. Surgical treatment of pigmented villonodular synovitis of the hip. J Bone Joint Surg Am 2005; 87: 1019-1024
• 24 Ogilvie-Harris DJ, McLean J, Zarnett ME. Pigmented villonodular synovitis of the knee. The results of total arthroscopic synovectomy, partial, arthroscopic synovectomy, and arthroscopic local excision. J Bone Joint Surg Am 1992; 74: 119-123
• 25 Yoo JJ, Kwon YS, Koo KH et al. Cementless total hip arthroplasty performed in patients with pigmented villonodular synovitis. J Arthroplasty. 25 552-557